Sunday, February 13, 2011 11:17:53 AM
A Re-Emerging Challenge: New Opportunities for Dengue Research Collaboration
San Juan, Puerto Rico
February 16, 2011 - February 18, 2011
CRDF Global's Stacey Gomelsky will attend "A Re-Emerging Challenge: New Opportunities for Dengue Research Collaboration" Conference.
The objective of this scientific meeting is to provide a forum for exchange of current information regarding Dengue research, identify research gaps and priorities and to promote and stimulate new or enhanced research collaborations in the Americas. The topics addressed will cover a broad spectrum of research areas related to Dengue, including basic and applied science in areas from epidemiology, virology, vector biology, pathogenesis, immunology, and the development of diagnostics, therapeutics and vaccines.
Following this conference, CRDF Global will announce a collaborative grant competition for participants of the conference.
San Juan, Puerto Rico
February 16, 2011 - February 18, 2011
CRDF Global's Stacey Gomelsky will attend "A Re-Emerging Challenge: New Opportunities for Dengue Research Collaboration" Conference.
The objective of this scientific meeting is to provide a forum for exchange of current information regarding Dengue research, identify research gaps and priorities and to promote and stimulate new or enhanced research collaborations in the Americas. The topics addressed will cover a broad spectrum of research areas related to Dengue, including basic and applied science in areas from epidemiology, virology, vector biology, pathogenesis, immunology, and the development of diagnostics, therapeutics and vaccines.
Following this conference, CRDF Global will announce a collaborative grant competition for participants of the conference.
Recent NNVC News
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
